Toss a coin in the Trevi Fountain is ranked #5 out of 26 things to do in Rome. See pictures and our review of Toss a coin in the Trevi Fountain.

Rome has unveiled the most drastic facelift for the Trevi Fountain in its 252-year history, the latest in a series of privately-funded restorations to Italy's prized landmarks.

The Trevi Fountain is one of the most famous landmarks in the Italian capital. Completed in 1762, it was designed by architect Nicola Salvi. Famously tourists are encouraged to throw a coin in ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in ...

Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in ...

Rome, January 24 - Barriers are to be put around the Trevi Fountain to stop tourists sitting on the iconic Roman monument, according to a majority amendment approved by the city council assembly ...

NEW HAVEN, Conn. - Trevi Therapeutics, Inc. (NASDAQ: TRVI), a $635 million market cap biopharmaceutical company focused on developing treatments for chronic cough and idiopathic pulmonary fibrosis ...

Rome - The hottest day in Rome so far this year brought relief for one and entertainment for many on Sunday as a woman took a skinny-dip in the Trevi Fountain. Identified only as Roberta, the ...

Fountain of Youth is a robust showcase of Guy Ritchie’s eye for action, but it falls short of capturing the magic of the quintessential treasure-hunting movies it’s so clearly trying to replicate.

Harry Van Vliet just shared a look at his life with Brianna Duffield after BDDU Season 3. Read on to see where they stand today.

Oppenheimer maintained its Outperform rating on Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares and lifted the price target from $20 to $23. In a research note, the analyst informs investors that ...

On Tuesday, Oppenheimer increased its price target for Trevi Therapeutics Inc. (NASDAQ:TRVI) to $23 from $20, while maintaining an Outperform rating.This heightened optimism is driven by positive ...